5-IAI

From Wikipedia, the free encyclopedia
Jump to: navigation, search
5-IAI
5-iodo-2-aminoindane.svg
Systematic (IUPAC) name
5-iodo-2,3-dihydro-1H-inden-2-amine
Clinical data
Pregnancy cat. ?
Legal status Uncontrolled
Routes Oral, Insufflated, Rectal
Identifiers
CAS number 132367-76-1 N
ATC code None
PubChem CID 131506
ChemSpider 116224 YesY
UNII 7X16E45Y1X YesY
Chemical data
Formula C9H10IN 
Mol. mass 259.087 g/mol
 N (what is this?)  (verify)

5-Iodo-2-aminoindane (5-IAI) is a drug which acts as a releasing agent of serotonin, norepinephrine, and dopamine.[1] It was developed in the 1990s by a team led by David E. Nichols at Purdue University.[2] 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans.[2] Unlike related aminoindane derivatives like MDAI and MMAI, 5-IAI causes some serotonergic neurotoxicity in rats, but is substantially less toxic than its corresponding amphetamine homologue pIA, with the damage observed barely reaching statistical significance.[1]

See also[edit]

References[edit]

  1. ^ a b Johnson MP, Conarty PF, Nichols DE (July 1991). "[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues". European Journal of Pharmacology 200 (1): 9–16. doi:10.1016/0014-2999(91)90659-E. PMID 1685125. 
  2. ^ a b Nichols DE, Johnson MP, Oberlender R (January 1991). "5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine". Pharmacology, Biochemistry, and Behavior 38 (1): 135–9. doi:10.1016/0091-3057(91)90601-W. PMID 1826785.